Parasite-resistant variants in African genomes: implications for global genetic medicine

African populations harbor the highest genetic diversity globally, shaped by over 300 000 years of adaptation to the continent's diverse ecology. Parasitic infections like malaria (Plasmodium falciparum) and sleeping sickness (Trypanosoma brucei) have driven genetic selection for resistance. For instance, the sickle-cell mutation (HBB:c.20A>T) offers malaria protection but causes sickle-cell disease. Similarly, APOL1 gene variants (G1/G2) protect against sleeping sickness but increase the risk of kidney disease. While these variants provide survival benefits, they also pose significant health challenges. This highlights the need for research into their effects on organ systems, epistasis, and potential therapies. Drugs targeting APOL1 synthesis are being tested to treat APOL1-mediated nephropathy, and exploring African genomes may uncover new parasite-resistant variants, advancing global genomic medicine.